• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
Home » Earnings: Allergan sheds poor lap-band sales, stays pretty in Q2

Earnings: Allergan sheds poor lap-band sales, stays pretty in Q2

August 1, 2012 By MassDevice staff

Allergan logo

Allergan (NYSE:AGN) is sitting pretty, following stronger than expected results for the 2nd quarter, despite a precipitous drop-off in the company’s Lap-Band obesity treatment business.

The Irvine, Calif-based medical aesthetic medical device and pharmaceutical company reported net earnings of $295.4 million on $1.49 billion in sales, a 19% increase from the $246.6 million on $1.42 billion in sales the company reported for the same period last year.

The company’s medical device business grew 4% to $254.8 million, compared to $245.1 million for the same period last year. Allergan shrugged off slow sales in its Lap-Band weight loss treatment, which fell 24% to $41.3 million for the 3-month period ended June 30, compared to $54.4 million for the same period last year.

Allergan CEO David Pyott said the slide in Lap-Band sales was due to a combination of factors including reimbursement pressures and continuing softness in the bariatrics business overall.

He told investors during a conference call that the company has "directed considerable" effort to improving the reimbursement landscape for Lap-Band surgery but that "in a time of high unemployment, high patient co-pays are a barrier."

He added that on a macro economic level gastric banding procedures are losing market share to sleeve gastroectomy, a procedure where a portion of the stomach is removed. Allergan’s Lap-Band device is implanted during surgery and uses an adjustable silicon ring to constrict the upper portion of the stomach.

Lap-band sales have been slow all year, down 20% through the first 6 months to $85.3 million. Allergan officials expect the business to pull in about $170 million in 2012.

Allergan’s breast aesthetics business fared much better, notching a 6% increase in sales to $101.2 million, and the company’s facial aesthetics business jumped 18% to $112.3 million.

On Wall Street, shares of Allergan stock were up 5% in afternoon trading on news that the company had increased its full-year earnings guidance to $4.15 to $4.19 per share on sales between $5.65 billion and $5.8 billion, compared with earlier estimates of $4.13 to $4.19.

Filed Under: Cosmetic/Aesthetic, News Well, Wall Street Beat Tagged With: 2012, Allergan, Bariatrics, Q2

More recent news

  • Aurora Spine begins first procedures with Aero lumbar fusion system
  • Caranx Medical surgical robot TaviPilot AI software wins FDA clearance
  • InspireMD launches carotid stent in U.S. after FDA approval
  • Neuros Medical raises $56M Series D to support nerve stim tech
  • CorWave reports first-in-human LVAD implant

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy